Amidst concerns about global growth and a stronger euro, the pan-European STOXX Europe 600 Index recently ended slightly lower, reflecting mixed performances across major European stock indexes. In such a market landscape, investors often seek opportunities that balance potential with financial resilience. Penny stocks—often representing smaller or newer companies—remain relevant for those willing to explore beyond established names, offering unique growth possibilities when backed by solid financials.
Name
Share Price
Market Cap
Financial Health Rating
Ariston Holding (BIT:ARIS)
€4.26
€1.47B
★★★★★☆
Maps (BIT:MAPS)
€3.37
€44.76M
★★★★★★
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.37
€247.45M
★★★★★★
Cellularline (BIT:CELL)
€3.14
€66.23M
★★★★★☆
Euroland Société anonyme (ENXTPA:ALERO)
€3.20
€10.15M
★★★★★★
ForFarmers (ENXTAM:FFARM)
€4.475
€395.52M
★★★★★★
High (ENXTPA:HCO)
€3.69
€72.54M
★★★★★★
Deceuninck (ENXTBR:DECB)
€2.11
€291.65M
★★★★★★
Netgem (ENXTPA:ALNTG)
€0.93
€31.36M
★★★★★★
Click here to see the full list of 330 stocks from our European Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Cellectis S.A. is a clinical stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €175.03 million.
Operations: The company’s revenue is derived entirely from its therapeutics segment, amounting to $63.44 million.
Market Cap: €175.03M
Cellectis S.A., a clinical-stage biotech firm, has shown significant revenue growth with US$18.19 million in Q2 2025 compared to US$9.5 million the previous year, though it remains unprofitable with a net loss of US$23.74 million for the quarter. Despite high volatility and negative return on equity, the company trades at a good value relative to peers and maintains more cash than debt, providing some financial stability. Recent strategic engagements at major healthcare conferences underscore its commitment to advancing its gene-editing technologies amid ongoing financial challenges and limited cash runway of less than one year if current trends persist.
ENXTPA:ALCLS Debt to Equity History and Analysis as at Sep 2025
Simply Wall St Financial Health Rating: ★★★★☆☆
Story Continues